Endocardial Stem Cells Approach Efficacy

NCT ID: NCT00841958

Last Updated: 2012-04-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

250 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-02-28

Study Completion Date

2011-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this study is to test that endocardial stem cells implantation in patients who have CAD, low ejection fraction and signs of HF without possibility of CABG and PCI or despite on previous revascularization improves long-term survival compared to MED alone

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myocardial Ischemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Autologous bone marrow mononuclear stem cells or peripheral blood stem cells

Cells concentration is 150х106 cells/ml (2ml) with CD34+ cells=2.5±1.44%

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men and women who are not of childbearing potential
* Age 21-75 years.
* Patients with CAD, NYHA and CCS angina III-IV functional class
* LVEF less than 35% measured by echocardiography or SPECT within three months of study entry
* Unsuitable for initial or repeated conventional revascularization (CABG or PCI)

Exclusion Criteria

* Failure to provide informed consent.
* Plan for PCI or CABG.
* Non-cardiac illness with a life expectancy of less than 3 year.
* Conditions/circumstances likely to lead to poor treatment adherence (e.g., history of poor compliance, alcohol or drug dependency, psychiatric illness, no fixed abode).
* Previous heart, kidney, liver, or lung transplantation.
* Current participation in another clinical trial in which a patient is taking an investigational drug or receiving an investigational medical device.
* Recent acute myocardial infarction (AMI) within 90 days of study entry
* Successful coronary revascularization (СABG or PCI) within 12 months of study enrollment
* History of moderate to severe aortic stenosis or prosthetic aortic valve
* Permanent atrial fibrillation
* Thrombosis in LV, based on echocardiography data
Minimum Eligible Age

21 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Meshalkin Research Institute of Pathology of Circulation

NETWORK

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Evgeny A Pokushalov, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

State Research Institute of Circulation Pathology

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

State Research Institute of Circulation Pathology

Novosibirsk, , Russia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Russia

References

Explore related publications, articles, or registry entries linked to this study.

Pokushalov E, Romanov A, Chernyavsky A, Larionov P, Terekhov I, Artyomenko S, Poveshenko O, Kliver E, Shirokova N, Karaskov A, Dib N. Efficiency of intramyocardial injections of autologous bone marrow mononuclear cells in patients with ischemic heart failure: a randomized study. J Cardiovasc Transl Res. 2010 Apr;3(2):160-8. doi: 10.1007/s12265-009-9123-8. Epub 2009 Sep 24.

Reference Type RESULT
PMID: 20560030 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

http://www.meshalkin.ru/

State Research Institute of Circulation Pathology Official Site

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RU002

Identifier Type: OTHER

Identifier Source: secondary_id

SCVM-029

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

MSCs for Prevention of MI-induced HF
NCT05043610 COMPLETED PHASE3
Autologous Cell Therapy for Ischemic Heart Failure
NCT01353690 TERMINATED PHASE1/PHASE2
Stem Cell in Acute Myocardial Infarction
NCT04340609 COMPLETED PHASE1/PHASE2
Mesenchymal Stem Cells and Myocardial Ischemia
NCT01076920 COMPLETED PHASE1/PHASE2
Progenitor Cell Therapy in Dilative Cardiomyopathy
NCT00284713 COMPLETED PHASE1/PHASE2